Amarin Tells Fed. Circ. Vascepa Patents Didn't Get Fair Shot
Amarin Pharma Inc. urged the full Federal Circuit Friday to revive six patents on its heart drug Vascepa, saying the court must prevent important types of evidence that a patent is...To view the full article, register now.
Already a subscriber? Click here to view full article